Non-Alcoholic Fatty Liver Disease Management
Diagnostic Approach
- The American Association for the Study of Liver Diseases recommends a clinical presentation of non-alcoholic fatty liver disease (NAFLD) with newly diagnosed type 2 diabetes, given the markedly elevated liver enzyme levels with mild transaminase elevations in the context of metabolic syndrome 1, 2
- Mandatory initial investigations include alcohol intake quantification, viral hepatitis screening, complete metabolic syndrome assessment, complete blood count, and abdominal ultrasound to confirm hepatic steatosis 2, 3
Risk Stratification
- The European Association for the Study of the Liver recommends calculating fibrosis risk scores immediately, using scores such as FIB-4, NFS, ELF, or FibroTest to assess the risk of advanced liver disease 3, 4, 5
- The FIB-4 score is calculated using age, AST, ALT, and platelet count, with a score of <1.3 indicating low risk, 1.3-2.67 indicating intermediate risk, and >2.67 indicating high risk 5
Management Strategy
- The American College of Gastroenterology recommends weight loss as the cornerstone of therapy, with a target of 7-10% total body weight loss through gradual reduction of 0.5-1 kg per week maximum 5
- A Mediterranean diet pattern with reduced saturated fats and refined carbohydrates is recommended, along with 150-200 minutes per week of moderate-intensity aerobic activity in 3-5 sessions 1, 5
- For newly diagnosed type 2 diabetes with NAFLD, GLP-1 receptor agonists (liraglutide or semaglutide) are recommended as first-line therapy, with metformin as initial or adjunctive therapy if liver function is not severely impaired 5
Monitoring Protocol
- The American Association for the Study of Liver Diseases recommends initial monitoring of liver enzymes, fasting glucose, HbA1c, lipid panel, weight, and BMI, with long-term monitoring of FIB-4 score, liver enzymes, and hepatocellular carcinoma surveillance 2, 3, 5